New to Meducation?
Sign up
Already signed up? Log In
view moderators

AcuteCoronarySyndrome

Category

Preview
24
774

Acute Coronary Syndrome and the ECG

A beginners guide to understanding the principles of ECG changes in Acute Coronary Syndrome (ACS) and how to differentiate beteeen a STEMI, NSTEMI and Unstable angina.  
Laurence Sharifi
over 8 years ago
Preview
30
2323

Ischemic Heart Disease

Covers the pathogenesis myocardial ischemia, risk factors (eg: atherosclerosis), the spectrum of acute coronary syndrome, reliable investigation and treatment of choice.  
malek ahmad
almost 7 years ago
Preview
1
36

An Audit of Prescribing LMWHs in Acute Coronary Syndrome

A brief overview of an audit I undertook.  
katrina lines
over 6 years ago
Preview
1
24

Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome

Stream Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome by BMJ talk medicine from desktop or your mobile device  
SoundCloud
over 5 years ago
Preview
1
25

Statins after acute coronary syndrome: a missed opportunity

Stream Statins after acute coronary syndrome: a missed opportunity by BMJ talk medicine from desktop or your mobile device  
SoundCloud
over 5 years ago
Artworks 000071772926 kq56gz t200x200
1
26

Maintenance of statin use over 3 years following acute coronary syndromes

Stream Maintenance of statin use over 3 years following acute coronary syndromes by BMJ talk medicine from desktop or your mobile device  
SoundCloud
over 5 years ago
Preview
1
23

Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome

Stream Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome by BMJ talk medicine from desktop or your mobile device  
SoundCloud
about 5 years ago
Preview
1
30

Statins after acute coronary syndrome: a missed opportunity

Stream Statins after acute coronary syndrome: a missed opportunity by BMJ talk medicine from desktop or your mobile device  
SoundCloud
about 5 years ago
Preview
1
21

Maintenance of statin use over 3 years following acute coronary syndromes

Stream Maintenance of statin use over 3 years following acute coronary syndromes by BMJ talk medicine from desktop or your mobile device  
SoundCloud
about 5 years ago
Preview
2
131

Pathophysiology and management of acute coronary syndromes

Stream Pathophysiology and management of acute coronary syndromes by BMJ talk medicine from desktop or your mobile device  
SoundCloud
over 4 years ago
Preview
0
12

Cardiovascular: BRILINTA receives US FDA approval for new administration option

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) patients who are unable to swallow BRILINTA...  
medicalnewstoday.com
over 4 years ago
Preview
0
8

The Dynamics of In-Hospital and Post-Discharge ACS Management CME

This activity was developed for cardiologists and other healthcare professionals involved in the in-hospital and post-hospital discharge management of acute coronary syndrome patients.  
medscape.org
over 4 years ago
Preview
0
24

Chest Pain: What is the Value of a Good History? - R.E.B.E.L. EM - Emergency Medicine Blog

Getting a good chest pain history can give you specific aspects of the history that can increase or decrease the likelihood that a patient has acute coronary syndrome (ACS) and/or AMI  
rebelem.com
over 4 years ago
Preview
0
18

Episode 20 – Anticoagulation

(ITUNES OR LISTEN HERE) The Free Open Access Medical Education (FOAM) We review Dr. Rory Spiegel's, A Case of Identity Part Two, post on EMNerd which is essentially a take down of dual antiplatelet therapy (DAT) in acute coronary syndrome (ACS).  The bottom line?  There's no demonstrable and clinically significant benefit from DAT as demonstrated in the trials…  
foamcast.org
over 4 years ago
Preview
0
16

Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome

Stream Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome by BMJ talk medicine from desktop or your mobile device  
feeds.bmj.com
over 4 years ago
Preview
0
17

Statins after acute coronary syndrome: a missed opportunity

Stream Statins after acute coronary syndrome: a missed opportunity by BMJ talk medicine from desktop or your mobile device  
feeds.bmj.com
over 4 years ago
Preview
0
13

Maintenance of statin use over 3 years following acute coronary syndromes

Stream Maintenance of statin use over 3 years following acute coronary syndromes by BMJ talk medicine from desktop or your mobile device  
feeds.bmj.com
over 4 years ago
Preview
0
17

A Secondary Examination of The Adventure of the Cardboard Box - EM Nerd

In November of 1995 stroke care as we know it drastically and permanently changed. With the publication of NINDS-2 the NEJM ushered in the interventional era of acute ischemic stroke (1). No longer were we powerless in our management of these patients. Finally we could offer them more than an aspirin to chew on, a corner to sit in, and an appointment with a neurologist in the morning.  And yet NINDS-2 was not the first trial examining thrombolytic therapy for acute ischemic stroke. In fact three trials were published prior to NINDS-2 all of which were negative (NINDS-1, MAST-I, ECASS-1) with two finding an increase in mortality in patients given thromblytics (1,2,3). With the publication of NINDS-2 all this was forgotten. NINDS-2 was impressively positive, demonstrating a 13% absolute increase in patients who were given tPA that were alive and independent (mRS of 0 or 1) at 90 days (1). Supporters justified the 6% absolute increase in symptomatic intracranial hemorrhage by arguing that it did not increase 90-day mortality (21% vs 17%). Despite these impressive results there were still three negative trials to account for. What made NINDS-2 different than all the trials that came before it? Was it the agent? Supporters claim that tPA was the superior thrombolytic and we should ignore all trials studying other agents. Was it time? NINDS examined patients who received tPA within 180 minutes of symptom onset (half in under 90 minutes); two of the earlier trials examined patients who received thrombolytc therapy over a much broader treatment window. Was it the patient population? The authors of NINDS used very strict selection criteria to determine which patients were acceptable candidates. There was of course a fourth reason proposed by a less enthusiastic contingent, that being random chance. This more skeptical party posited that an intervention that possesses little or no efficacy, if studied enough times would eventually demonstrate positive results simply by chance alone. They reminded the more eager supporters of tPA therapy that though the findings of NINDS-2 may be true, taking these results at face value without further validation was not only bad science, but even worse medicine. Despite these warnings the FDA fast tracked the approval of tPA for acute ischemic stroke in under 3-hours and all other trials attempting to validate this benefit were abandoned. As Elliot Grosbard, Genentech scientist, said in internal communications in regards to further trials comparing streptokinase to tPA for acute coronary syndrome;  
emnerd.com
over 4 years ago
Preview
0
12

Dr. Smith's ECG Blog: 40 Minute Lecture with Many Cases: Complications of Acute Coronary Syndrome.

Instructive ECGs in Clinical Context ----Archives, Popular Posts, and an Index of all ECGs are down the right-hand side.  
hqmeded-ecg.blogspot.com
over 4 years ago